SFCM
ELVN icon

Seven Fleet Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Seven Fleet Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.43M Buy
164,030
+64,077
+64% +$1.78M 2.02% 8
2025
Q4 		$1.54M Buy
+99,953
New +$1.99M 1.04% 15

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Seven Fleet Capital Management's ELVN Position: Q1 2026 in Review

Seven Fleet Capital Management increased its Enliven Therapeutics (ELVN) stake by 64% in Q1 2026, buying an estimated $1.78M and bringing the position to 164,030 shares worth $6.43M. The position accounts for 2.02% of the portfolio, ranked #8.

Seven Fleet Capital Management first reported a position in ELVN in Q4 2025 and has held it in 2 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Seven Fleet Capital Management held 164,030 shares of Enliven Therapeutics worth $6.43M as of Q1 2026.
  • Seven Fleet Capital Management bought 64,077 Enliven Therapeutics shares in Q1 2026, an estimated $1.78M.
  • Enliven Therapeutics made up 2.02% of Seven Fleet Capital Management's portfolio in Q1 2026, its #8 holding.
  • Seven Fleet Capital Management first reported a position in Enliven Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.